Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - gemcitabine hydrochloride - concentrate for solution for infusion - 38 milligram(s)/millilitre - pyrimidine analogues; gemcitabine

Amerika Serikat - Inggris - NLM (National Library of Medicine)

evonik corporation - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - as the drum is weighed in the warehouse, this label is applied with the net weight and storage location: material number: material description: batch: to: su: storage unit quantity: kg gemcitabine hydrochloride put-away label material number 99144329 storage unit net weight xx kg lot/batch old material number qa383e qr code box storage conditions: warehouse temperature temperature conditions: 8 to 40°c hazards: skin permeable. mutagen. irritant (eyes). reproductive. blood. highly potent. acute toxicity, oral. acute toxicity, dermal. health 2 fire 1 reactivity 1 special r (reproductive hazard) evonik corporation 1650 lilly road lafayette, indiana 47909 usa phone: 765-477-4300 fax: 765-477-4291 evonik: leading beyond chemistry emergency information: chemtrec 800-424-9300 gemcitabine hydrochloride put-away label material number: 99144329 storage unit number net quantity: kg qr code lot/batch number: old material number: qa383e storage conditions: warehouse temperatur temperature condition: 8°c to 40°c skin perm

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - gemcitabine hydrochloride, quantity: 1.14 g (equivalent: gemcitabine, qty 1 g) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; sodium acetate trihydrate - treatment of patients with locally advanced or metastatic non-small cell lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed >six months following platinum based therapy.

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - gemcitabine hydrochloride - solution for infusion - 100mg/1ml

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - gemcitabine hydrochloride - solution for infusion - 100mg/1ml

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - gemcitabine hydrochloride - solution for infusion - 100mg/1ml

Armenia - Inggris - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - gemcitabine (gemcitabine hydrochloride) - concentrate for solution for i/v infusion - 100mg/ml

Armenia - Inggris - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - gemcitabine (gemcitabine hydrochloride) - concentrate for solution for i/v infusion - 100mg/ml

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.